[BostonCard]

Because it is an IV medicine intended to be taken daily, it will be difficult to give to high risk outpatients, plus it hasn’t been shown to prevent a hospitalization.  Gilead is making an inhaler formulation, made to be given through an inhaler, and intended for outpatients.

As to the price, on average remdeaivir reduces the length of hospitalization by two days in hospitalized patients.  So, they are pricing the drug comparing it to the cost of being hospitalized for two extra days.

BC

[BostonCard]

Because it is an IV medicine intended to be taken daily, it will be difficult to give to high risk outpatients, plus it hasn’t been shown to prevent a hospitalization.  Gilead is making an inhaler formulation, made to be given through an inhaler, and intended for outpatients.

As to the price, on average remdeaivir reduces the length of hospitalization by two days in hospitalized patients.  So, they are pricing the drug comparing it to the cost of being hospitalized for two extra days.

BC